William Blair Investment Management LLC Purchases Shares of 232,597 Lantheus Holdings, Inc. $LNTH

William Blair Investment Management LLC purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 2nd quarter, Holdings Channel.com reports. The fund purchased 232,597 shares of the medical equipment provider’s stock, valued at approximately $25,804,000.

A number of other hedge funds have also recently made changes to their positions in the business. Western Wealth Management LLC bought a new position in shares of Lantheus during the 1st quarter valued at $25,000. Osterweis Capital Management Inc. bought a new stake in Lantheus in the second quarter worth $36,000. Allworth Financial LP purchased a new stake in Lantheus during the second quarter valued at about $49,000. Smartleaf Asset Management LLC boosted its position in Lantheus by 63.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 197 shares during the period. Finally, Bessemer Group Inc. grew its stake in shares of Lantheus by 221.2% during the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 354 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

LNTH has been the subject of a number of recent research reports. William Blair set a $102.50 target price on Lantheus in a research note on Monday, August 3rd. Citigroup restated an “outperform” rating on shares of Lantheus in a research report on Friday, May 8th. Weiss Ratings cut Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, August 13th. Mizuho lowered their price objective on Lantheus from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Wednesday, July 29th. Finally, Truist Financial lowered Lantheus from a “buy” rating to a “hold” rating and dropped their price objective for the company from $125.00 to $102.50 in a research note on Monday, August 3rd. Four research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $108.11.

Lantheus Stock Performance

Lantheus stock opened at $99.97 on Friday. The company has a current ratio of 3.06, a quick ratio of 2.89 and a debt-to-equity ratio of 0.43. The firm has a 50-day moving average of $104.08 and a 200-day moving average of $90.35. The firm has a market cap of $6.53 billion, a P/E ratio of 24.15 and a beta of -0.03. Lantheus Holdings, Inc. has a 1-year low of $49.67 and a 1-year high of $111.86.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.30 by $0.25. The company had revenue of $388.18 million for the quarter, compared to the consensus estimate of $363.23 million. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.Lantheus’s revenue was up 2.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.57 EPS. Sell-side analysts expect that Lantheus Holdings, Inc. will post 4.48 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.